ATP4A
Potassium-transporting ATPase alpha chain 1
As of the edition of 20 October 2026, ATP4A (potassium-transporting ATPase alpha chain 1, UniProt P20648) has 13 drugs tested at it and 28 companies on the list, 1 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P20648
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Digestive system; Cancer; Immune system; Lungs and airways; Infections; Skin and connective tissue; Nutrition and metabolism; Blood and lymph
- Registered trials of its drugs
- 1,234
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 7 |
| Active | 3 |
| Went quiet | 3 |
| Total | 13 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Omeprazole | Marketed | Phase 4 | none listed |
| Esomeprazole | Marketed | Phase 4 | none listed |
| Rabeprazole | Marketed | Phase 4 | none listed |
| Pantoprazole | Marketed | Phase 4 | Ends 2027 |
| Lansoprazole | Marketed | Phase 4 | none listed |
| Vonoprazan | Marketed | Phase 4 | Ends 2032 |
| Tegoprazan | Active | Phase 4 | none listed |
| Dexlansoprazole | Marketed | Phase 4 | none listed |
| Abeprazan | Active | Phase 4 | none listed |
| Ilaprazole | Active | Phase 4 | none listed |
| PN 400 | Went quiet | Phase 1 | none listed |
| D961H | Went quiet | Phase 3 | none listed |
12 of 13 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 6 |
| Engaged | 17 |
| Undetermined | 4 |
| Total on the list | 28 |
| Company | Route |
|---|---|
| AstraZeneca | Route B |
| Johnson & Johnson | Route B |
| Pfizer | Route B |
The other 25 companies at ATP4A
In the product28 companies in all; 25 are not named here, and no score is.
See the 28 companies at ATP4A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.